Scientists in Seattle plan to pay people to catch malaria in order to test the safety and efficacy of new vaccines.
The Seattle Biomedical Research Institute and the PATH Malaria Vaccine Initiative are collaborating to build a Human Challenge Center at SBRI to test new interventions against the deadly malaria parasite. "This center will allow us to greatly increase our ability to evaluate whether a new vaccine formulation should advance to testing in clinical trials in malaria-endemic populations," Dr. Christian Loucq of MVI said Wednesday in a statement.
The laboratory's Malaria Clinical Trials Center will be one of only a handful of facilities of its kind in the world. Volunteers inoculated with a malaria vaccine candidate will be deliberately infected with malaria through the bite of malaria-infected mosquitoes to assess whether or not the candidate vaccine can prevent or delay malaria infection.
The Seattle Times said the strain of malaria used in the testing is a cloned strain that can be quickly cured. More than 900 people have participated in similar tests at Walter Reed Army Institute of Research. There are also labs in Britain and the Netherlands, the newspaper said.
Copyright 2008 by United Press International
Related stories:
Gates: $258 million for malaria research
The Bill and Melinda Gates Foundation has given $258 million in malaria research grants.
The foundation says malaria kills an estimated 2,000 African children each day and takes the lives of more than 1 million people worldwide annually.
How the malaria parasite hijacks human red blood cells
A new study—done on a scale an order of magnitude greater than anything previously attempted in the field of malaria—has uncovered an arsenal of proteins produced by the malaria parasite that allows it to hijack and remodel human red blood cells, leaving the oxygen-carrying cells stiff and sticky. Those effects on the blood cells play a major role in the development of malaria, a disease responsible for millions of deaths every year, the researchers report in the July 11th issue of the journal
Cell, a Cell Press publication.
Parasite vaccines within reach
Even though parasites are complex creatures, the mammalian immune response to them is surprisingly simple, leading University of California, Berkeley, researchers to predict that creating vaccines for parasitic diseases such as malaria may be more straightforward than initially thought.
Engineers create new technique for malaria diagnosis
Researchers from the Universities of Exeter and Coventry have developed the first new technique for diagnosing malaria able to challenge the rapid diagnostic tests (RDTs) currently used in the field.
Discovery to hasten new malaria treatments, vaccines for children
April 25 is World Malaria Day 2008 and despite the grim statistics out of Africa there’s cause for celebration. Florida State University biologists have discovered an autoimmune-like response in blood drawn from malaria-infected African children that helps to explain why existing DNA-based anti-malaria vaccines have repeatedly failed to protect them.
With annual deaths from malaria on the rise: Scientists ask 'where is all the money going?'
A new study in the April issue of the
American Journal of Tropical Medicine and Hygiene, asks the question "With more than $220 million dollars dedicated to malaria treatment and prevention, why is the annual mortality rate from malaria on the rise?"
Discovery could lead to attack on mosquito-borne disease
Cornell researchers have identified a mating mechanism that possibly could be adapted to prevent female mosquitoes from spreading the viruses that cause dengue fever, second only to malaria as the most virulent mosquito-borne disease in the tropical world.
Tropical disease experts call for a 'Global Fund to Fight Neglected Tropical Diseases'
An international team of tropical disease control experts has urged the global health and development community, and particularly the G8 leaders, to establish a new financing mechanism to combat the neglected tropical diseases (NTDs) of poverty.